CytoSite Bio
PrivateLast Round
Seed
Sep 24, 2020
Total Funding Raised
$7.87M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
CytoSite Bio operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Seed round in September 2020.
CytoSite Bio is a biotechnology company that develops Granzyme B-targeted radiopharmaceuticals and PET imaging agents to assess and improve immunotherapy efficacy in cancer and autoimmune disease patients.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Imaging, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CytoSite Bio Comparables
Compare CytoSite Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CellSight Technologies | 87% | |
| Telix Pharmaceuticals | 79% | |
| GE HealthCare Technologies Inc. | 78% |
For institutional investors. Book with your work email.
CytoSite Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Sep 24, 2020 | ||||
| Series A | Aug 9, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
CytoSite Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Seed |
| NIH RADx | Grant |
| Acorn Campus Taiwan | Seed |
| First Avenue Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 65% MoM.
- Mar 2, 2026
Monthly visitors grew 85% MoM.
For institutional investors. Book with your work email.
CytoSite Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about CytoSite Bio's valuation, stock price, and market status.
Is CytoSite Bio a public or private company?
CytoSite Bio is a private company.
What is the current stock price of CytoSite Bio?
CytoSite Bio is a private company, so its shares have no public market price. Caplight tracks CytoSite Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is CytoSite Bio worth (valuation)?
Valuation information for CytoSite Bio is not publicly available.
Can I buy CytoSite Bio stock?
CytoSite Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was CytoSite Bio's last funding round?
CytoSite Bio's most recent funding round was Seed on September 24, 2020.
Who are the main investors in CytoSite Bio?
Key investors in CytoSite Bio include National Cancer Institute, NIH RADx, Acorn Campus Taiwan, First Avenue Ventures.
Will CytoSite Bio IPO soon?
No public IPO plans have been announced for CytoSite Bio.
How can I track CytoSite Bio secondary market activity?
Caplight tracks bids, offers, and trades in CytoSite Bio's shares on secondary markets.